Inicio › Enfermedad de Crohn › Washington
Ensayos clínicos de Enfermedad de Crohn en Washington
22 estudios sobre Enfermedad de Crohn buscan participantes en Washington.
Ciudades en Washington
Texto oficial del estudio (inglés)
Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)
- Washington Gastroenterology - Tacoma ( Site 0295), Tacoma
ReclutandoFase 3
Todas las edades · Todos los sexos · Actualizado el 2 oct 2026 · NCT06651281A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
- University of Washington ( Site 5115), Seattle
- Washington Gastroenterology - Tacoma ( Site 5004), Tacoma
ReclutandoFase 3
Edades de 16 a 80 · Todos los sexos · Actualizado el 2 oct 2026 · NCT06430801Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
- Washington Gastroenterology - Bellevue /ID# 283966, Bellevue
- Washington Gastroenterology - Tacoma /ID# 284143, Tacoma
- The Vancouver Clinic /ID# 280497, Vancouver
ReclutandoFase 2
Edades de 18 a 75 · Todos los sexos · Actualizado el 2 oct 2026 · NCT07697456A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
- GI Alliance, Bellevue
ReclutandoFase 4
Edades de 18 a 80 · Todos los sexos · Actualizado el 30 sept 2026 · NCT06581328Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
- Virginia Mason Hospital and Medical Center /ID# 265574, Seattle
- Washington Gastroenterology - Tacoma /ID# 267302, Tacoma
ReclutandoFase 2
Edades de 18 a 75 · Todos los sexos · Actualizado el 25 sept 2026 · NCT06548542A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
- GI Alliance Tacoma, Tacoma
ReclutandoFase 2/3
Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT07196722A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
- University of Washington Medical Center, Seattle
ReclutandoFase 2
Edades de 18 a 75 · Todos los sexos · Actualizado el 25 sept 2026 · NCT06233461Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- Washington Gastroenterology - Tacoma, Tacoma
ReclutandoFase 3
Edades de 18 a 70 · Todos los sexos · Actualizado el 24 sept 2026 · NCT06937099An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- GI Alliance - Bellevue-Site Number: 8400143, Bellevue
- The Vancouver Clinic Inc. P.S.-Site Number: 8400090, Vancouver
ReclutandoFase 3
Edades de 16 a 80 · Todos los sexos · Actualizado el 23 sept 2026 · NCT07184931A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- The Vancouver Clinic Inc. P.S.-Site Number: 8400090, Vancouver
ReclutandoFase 3
Edades de 16 a 80 · Todos los sexos · Actualizado el 23 sept 2026 · NCT07184944A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
- Washington Gastroenterology- GIA, Tacoma
ReclutandoFase 4
Edades de 18 a 70 · Todos los sexos · Actualizado el 9 sept 2026 · NCT06045754Familial Inflammatory Bowel Disease Early Risk
- Seattle Children's Hospital, Seattle
ReclutandoEstudio observacionalSe aceptan voluntarios sanos
Edades de 0 a 55 · Todos los sexos · Actualizado el 28 ago 2026 · NCT07791862A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
- GI Alliance Tacoma, Tacoma
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 28 ago 2026 · NCT07577843A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
- Seattle Children's Hospital, Seattle
ReclutandoFase 3
Edades de 2 a 17 · Todos los sexos · Actualizado el 24 ago 2026 · NCT05509777A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
- MultiCare Institute for Research & Innovation, Tacoma
ReclutandoFase 3
Edades de 2 a 17 · Todos los sexos · Actualizado el 3 ago 2026 · NCT06100289A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)
- Multicare Health System Institute for Research and Innovation, Tacoma
ReclutandoFase 3
Edades de 2 a 17 · Todos los sexos · Actualizado el 22 jun 2026 · NCT06405087Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease
- Seattle Children's Hospital, Seattle
ReclutandoFase 4
Edades de 6 a 17 · Todos los sexos · Actualizado el 27 may 2026 · NCT05781152A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
- Swedish Cancer Institute, Seattle
- University of Washington Medical Center - Montlake, Seattle
ReclutandoFase 3
Edades de 18 a 65 · Todos los sexos · Actualizado el 27 may 2026 · NCT06227910Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
- University of Washington, Seattle
ReclutandoFase 2
Edades de 18 a 75 · Todos los sexos · Actualizado el 27 abr 2026 · NCT06456593Seattle Spatial Transcriptomic Research in Inflammatory Bowel Disease Evaluation (STRIDE)
- Seattle Children's Hospital, Seattle
ReclutandoEstudio observacional
Edades de 6 a 21 · Todos los sexos · Actualizado el 24 abr 2026 · NCT06315179A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
- Mirador Therapeutics Selected Site, Bellevue
- Mirador Therapeutics Selected Site, Silverdale
- Mirador Therapeutics Selected Site, Tacoma
ReclutandoFase 2
Edades de 18 a 80 · Todos los sexos · Actualizado el 12 mar 2026 · NCT07113522Reverse-Engineering of Exclusive Enteral Nutrition (RE-EEN) in Crohn's Disease: A Multi-Center Trial
- Seattle Children's Hospital, Seattle
Reclutando
Edades de 8 a 21 · Todos los sexos · Actualizado el 12 jun 2025 · NCT06216899De ClinicalTrials.gov, datos obtenidos el 5 oct 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.